Thierry Buclin

Prof. Dr. Thierry Buclin

Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2008 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
APAndres Pascual
Andres Pascual
TCThierry Calandra
Thierry Calandra
SBSaskia Bolay
Saskia Bolay
TBThierry Buclin
Thierry Buclin
JBJacques Bille
Jacques Bille
OMOscar Marchetti
Oscar Marchetti
Background. Voriconazole is the therapy of choice for aspergillosis and a new treatment option for candidiasis. Liver disease, age, genetic polymorph

1 January 2001 in AIDS
Verified
Journal Article
Closed access
CMCatia Marzolini
Catia Marzolini
ATAmalio Telenti
Amalio Telenti
LDLaurent Arthur Decosterd
Laurent Arthur Decosterd
Gilbert GREUBGilbert GREUB
Gilbert GREUB
JBJérôme Biollaz
Jérôme Biollaz
TBThierry Buclin
Thierry Buclin
Limited information exists on the clinical usefulness of drug level monitoring for efavirenz, a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI). The aim of this study was to determine whether efavirenz plasma concentration monitoring could predict treatment failure and central nervous system (CNS) tolerability. Blood samples were obtained from 130 HIV-infected patients receiving efavirenz in combination with other antiretroviral agents for more than 3 months. Efavirenz plasma concentrations were measured by high-performance liquid chromatography. An evaluation of CNS side-effects was performed and the viral load, CD4 cell count and other clinical and laboratory data were assessed. In 85 patients, these measures were repeated at 3 month intervals. Efavirenz plasma levels (n = 226) were measured at an average of 14 h after drug intake. Drug concentrations ranged from 125 to 15 230 μg/l (median 2188). Large inter-patient (CV 118%) and limited intra-patient (CV 30%) variabilities were observed in efavirenz levels. Virological failure was observed in 50% of patients with low efavirenz levels (< 1000 μg/l) versus 22 and 18% in patients with 1000–4000 μg/l or more than 4000 μg/l, respectively. CNS toxicity was approximately three times more frequent in patients with high efavirenz levels (> 4000 μg/l) compared with patients with 1000–4000 μg/l. Treatment failure and CNS side-effects are associated with low and high efavirenz plasma levels, respectively. The important inter-individual variability in efavirenz levels strongly argues for dose adjustment on the basis of therapeutic drug monitoring to optimize treatment.

1 January 2004 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CMCatia Marzolini
Catia Marzolini
EPErik Paus
Erik Paus
TBThierry Buclin
Thierry Buclin
RKRichard B Kim
Richard B Kim

1 January 2002 in The Lancet
Verified
Journal Article
Closed access
JFJacques Fellay
Jacques Fellay
CMCatia Marzolini
Catia Marzolini
EMEmma R Meaden
Emma R Meaden
DBDavid J Back
David J Back
TBThierry Buclin
Thierry Buclin
SSSwiss HIV Cohort Study
Swiss HIV Cohort Study

1 January 2002 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
CEChin B. Eap
Chin B. Eap
TBThierry Buclin
Thierry Buclin
PBPierre Baumann
Pierre Baumann

1 June 2004 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SOSandrine Ostermann
Sandrine Ostermann
CCChantal Csajka
Chantal Csajka
TBThierry Buclin
Thierry Buclin
SLSerge Leyvraz
Serge Leyvraz
FLFerdy Lejeune
Ferdy Lejeune
RSRoger Stupp
Roger Stupp
Purpose: Scarce information is available on the brain penetration of temozolomide (TMZ), although this novel methylating agent is mainly used for the treatment of malignant brain tumors. The purpose was to assess TMZ pharmacokinetics in plasma and cerebrospinal fluid (CSF) along with its inter-individual variability, to characterize covariates and to explore relationships between systemic or cerebral drug exposure and clinical outcomes. Experimental Design: TMZ levels were measured by high-performance liquid chromatography in plasma and CSF samples from 35 patients with newly diagnosed or recurrent malignant gliomas. The population pharmacokinetic analysis was performed with nonlinear mixed-effect modeling software. Drug exposure, defined by the area under the concentration-time curve (AUC) in plasma and CSF, was estimated for each patient and correlated with toxicity, survival, and progression-free survival. Results: A three-compartment model with first-order absorption and transfer rates between plasma and CSF described the data appropriately. Oral clearance was 10 liter/h; volume of distribution (VD), 30.3 liters; absorption constant rate, 5.8 h−1; elimination half-time, 2.1 h; transfer rate from plasma to CSF (Kplasma→CSF), 7.2 × 10−4h−1 and the backwards rate, 0.76 h−1. Body surface area significantly influenced both clearance and VD, and clearance was sex dependent. The AUCCSF corresponded to 20% of the AUCplasma. A trend toward an increased Kplasma→CSF of 15% was observed in case of concomitant radiochemotherapy. No significant correlations between AUC in plasma or CSF and toxicity, survival, or progression-free survival were apparent after deduction of dose-effect. Conclusions: This is the first human pharmacokinetic study on TMZ to quantify CSF penetration. The AUCCSF/AUCplasma ratio was 20%. Systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety.